about
Diagnostic and prognostic tumor markers in the gastrointestinal tract.Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimensUndetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseDPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patientsRole of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer.Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.Effect of broccoli intake on markers related to oxidative stress and cancer risk in healthy smokers and nonsmokers.Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer.Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer.The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.Effect of 10-day broccoli consumption on inflammatory status of young healthy smokers.Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication.Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.The minimal effective exemestane dose for endocrine activity in advanced breast cancer.Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors.Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los AngAre capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissuesDid Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast CancerCirculating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic PerfusionEffect of a Tomato Drink Intervention on Insulin-Like Growth Factor (IGF)-1 Serum Levels in Healthy Subjectsc-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patientsThe luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markersTumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitorsA multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical resultsCan bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levelsEffect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer
P50
Q34277292-62208751-F9CC-4BDA-81B8-A8E2395878EFQ34309960-813E26FA-E679-4CF3-80BE-1C2BBF65CFDFQ35585759-4793A7B8-B492-4753-A12F-98BAB81D9C04Q36072520-FF697FF1-E384-4A2A-B26F-CC5D70201195Q36081653-BA19D9DF-9FEC-441D-BFFA-EA58B3B53F93Q37725536-4CC79F70-9D2C-4A3A-8F83-AA8265B07CDEQ37820653-ED317FC0-D4B9-4CD7-9ACA-2E330504E281Q38377594-30850B91-A797-4104-AB26-06C566D9B760Q40000704-9B6264EE-5251-4042-AB66-1939B7E6F522Q40756450-2A64BE60-EE39-4576-908D-E4B317035327Q43800032-4EF0DFEC-0FF2-4142-AE74-EED061A85A61Q43921035-378D4426-DEA7-4E76-888C-98471E8ED839Q43976058-2061495F-CCDC-4399-9860-8004C7153DC9Q44022304-4F1F4B55-211C-470E-8A97-DF2C5ED02525Q44101930-35433A4E-4331-4274-B77D-61E1ABE7A99EQ44592610-468DD05C-3998-4345-8BB4-EB74A158E2D0Q44926705-6BC46A80-73BA-4138-9000-CFB1576ED3D2Q45197443-3325B095-D45D-44A0-9973-72AA56DF7A9CQ46313317-CF08EA07-3810-4348-8570-8FD852DC659CQ46640564-5E62BC63-F748-44B1-85F6-2EAAE49F9E5EQ47376040-BB62172C-27AF-4FB7-BEAE-F5A7B8C35FC3Q48391442-5E2D627F-8713-4B4E-8986-CBEB5AA7C040Q50938443-919F218D-C16D-40C8-924A-5C2A25CACB1CQ53142866-98E86A68-6061-4C5F-8FE4-CF332E60777CQ53550064-FB366174-EF09-4266-B48E-9ACCE7E01C0EQ53738460-BCA05FAD-CB47-4305-A074-06801BF461A6Q54288887-785206A7-BE01-48DA-B8E2-22CE1FCC2C96Q57763490-7E5C3AF0-1146-45BB-874A-BF769A096D87Q59231397-0A4F42E8-8D11-4B9E-A86D-73C3DF362BDAQ59439765-47100F58-2E65-464B-B983-DB2FE624631DQ60168333-D4EBD5B0-0A14-47E6-A177-F9B3DF02E7E1Q60168334-446D6D7C-CE61-4F6E-ACBD-6E10019AD9CCQ60168336-25D55B69-5525-4BE0-BA11-474AFBCE8DC7Q60168349-901AA40E-21CC-4AEC-8DB4-F63F3F670623Q60168351-E4589404-454B-4BFC-936A-D286909CCC66Q60168353-AFBB2236-9726-4DDA-9CF0-03315CCCBD7AQ60168368-8E4BC033-DBF4-45D5-BA44-F2C06A00E0D5Q60168377-745ED7AC-70BB-4722-AA7A-674044D508A8Q60168382-A5CD12AF-0D72-447D-8138-1EEB41A9E5E6Q60168387-42156F46-F683-495D-894C-4A1B19658F09
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonia Martinetti
@ast
Antonia Martinetti
@en
Antonia Martinetti
@es
Antonia Martinetti
@nl
Antonia Martinetti
@sl
type
label
Antonia Martinetti
@ast
Antonia Martinetti
@en
Antonia Martinetti
@es
Antonia Martinetti
@nl
Antonia Martinetti
@sl
prefLabel
Antonia Martinetti
@ast
Antonia Martinetti
@en
Antonia Martinetti
@es
Antonia Martinetti
@nl
Antonia Martinetti
@sl
P1053
L-4011-2017
P1153
7003358832
P21
P31
P3829
P496
0000-0002-8020-7751